CARDINOR AS

Their core work

CARDINOR AS is a Norwegian diagnostics SME built around a single high-value clinical problem: identifying which cardiac patients with ventricular arrhythmias actually need an implantable cardioverter-defibrillator (ICD). They are developing secretoneurin (SN) — a neuropeptide released during cardiac stress — as the first blood biomarker capable of stratifying mortality risk in this patient group. Their work spans the full diagnostic development chain: from biomarker validation through ELISA-based in vitro diagnostics to clinical and health-economic case-building for regulatory and payer audiences. Their value proposition is not just clinical accuracy but cost savings — replacing costly, imprecise ICD implantations with evidence-based patient selection.

What they specialise in

How they've shifted over time

CARDINOR's H2020 participation is entirely confined to 2019-2020, with no early-period keyword data predating this window — both projects address the same technology from the outset. The progression visible within this narrow window is from feasibility to commercialization: SN-marker (EUR 50,000, CSA) appears to be a scoping or market validation study, while STRICT (EUR 119,805, SME Instrument Phase 1) is a full business innovation study targeting IVD market entry. There is no observable thematic pivot — this is a single-focus company that entered H2020 already knowing what it wanted to bring to market.

CARDINOR is moving from concept validation toward commercial IVD product launch, with the STRICT project building the regulatory and health-economic dossier needed to bring a secretoneurin diagnostic to clinical practice.

How they like to work

CARDINOR has acted as coordinator on both of its H2020 projects and records zero unique consortium partners — suggesting it ran both grants as a single-entity applicant, which is permitted under CSA and SME Instrument Phase 1 rules. This is the profile of a product-driven startup that uses EU funding to de-risk its own IP, not to build research networks. A future partner should expect to be brought in for a specific, bounded contribution (clinical validation, regulatory affairs, distribution) rather than co-ownership of the science.

With no recorded consortium partners across two projects, CARDINOR has no visible H2020 collaboration network. Their geographic footprint is Oslo-only based on available data, with no cross-border partnerships documented.

What sets them apart

CARDINOR appears to be the only H2020-funded entity building a commercial product specifically around secretoneurin as a cardiac biomarker — a molecule with strong published clinical evidence but no existing commercial assay. Their narrow focus on a single unmet need (ICD candidate selection) means they are not competing with broad cardiac panel developers like Roche Diagnostics or Abbott, but targeting a specific gap in arrhythmia management where current tools (echocardiography, Holter monitoring) have poor predictive value. For a consortium needing cardiac diagnostics expertise or a clinical partner seeking novel biomarker integration, they offer something genuinely differentiated.

Highlights from their portfolio

• STRICT
  The larger of the two grants (EUR 119,805) and the commercialization-stage project, STRICT builds the full clinical, regulatory, and economic case for secretoneurin as an IVD product — making it the foundation of CARDINOR's go-to-market strategy.
• SN-marker
  The earlier feasibility study that established the secretoneurin concept within H2020 and set up the subsequent STRICT application, demonstrating a deliberate two-stage EU funding strategy by a small SME.